INTEGRATE IIb: A Randomized Phase III Open Label Study of Regorafenib + Nivolumab Versus Standard Chemotherapy in Refractory Advanced Gastroesophageal Cancer (AGOC).
JOURNAL OF CLINICAL ONCOLOGY（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined